SC
ARQT icon

Stempoint Capital’s Arcutis Biotherapeutics ARQT Stock Holding History

Stempoint Capital’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-825,000
Closed -$516K – 47
2024
Q1 		$516K Buy
+825,000
New +$6.16M 0.14% 48

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Stempoint Capital's ARQT Position: Q2 2026 in Review

Stempoint Capital reduced its Arcutis Biotherapeutics (ARQT) stake by 76% in Q2 2026, selling an estimated $7.33M and leaving 98,945 shares worth $2.59M. The position accounts for 0.45% of the portfolio, ranked #59.

Stempoint Capital first reported a position in ARQT in Q4 2023 and has held it in 11 quarters since. The position peaked at $21.9M in Q1 2024. 273 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • Stempoint Capital held 98,945 shares of Arcutis Biotherapeutics worth $2.59M as of Q2 2026.
  • Stempoint Capital sold 314,847 Arcutis Biotherapeutics shares in Q2 2026, an estimated $7.33M.
  • Arcutis Biotherapeutics made up 0.45% of Stempoint Capital's portfolio in Q2 2026, its #59 holding.
  • Stempoint Capital first reported a position in Arcutis Biotherapeutics in Q4 2023 and has held it in 11 quarters since.
  • Stempoint Capital's Arcutis Biotherapeutics position peaked at $21.9M in Q1 2024.
  • 273 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Stempoint Capital's 13F filing for Q2 2026, filed 14 Aug 2026.